metastatic carcinoma

met·a·stat·ic car·ci·no·ma

a carcinoma that has appeared in a region remote from its site of origin, as in metastasis (2).
Synonym(s): secondary carcinoma
References in periodicals archive ?
Excisional biopsy of the penile nodule showing groups of metastatic carcinoma cells (hematoxylin and eosin stain x400).
Metastatic carcinoma from the female genitalia to the oral mucosa is exceptionally rare, with only 11 such cases having been previously reported in the English-language literature.
5,6) These features suggest a diagnosis of metastatic carcinoma, as also seen in the present case.
Metastatic carcinoma of the spermatic cord from colon cancer is extremely uncommon.
There was no evidence of vascular invasion and none of the seven lymph nodes excised contained any metastatic carcinoma [G2T1N0Mx].
Histology confirmed an infiltrating ductal carcinoma with metastatic carcinoma in 5 of the 10 axillary lymph nodes.
Bevacizumab, administered intravenously, was first approved in February 2004, in combination with 5-fluorouracil-based chemotherapy, for the first-line treatment of metastatic carcinoma of the colon or rectum.
Bevacizumab, administered intravenously, was first approved in 2004, in combination with 5-fluorouracil-based chemotherapy, for first-line treatment of metastatic carcinoma of the colon or rectum.
Metastatic carcinoma to the tongue: a report of two cases and a review of the literature.
Avastin is approved, in combination with intravenous 5-fluorouracil-based (5-FU) chemotherapy, for first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum and in combination with carboplatin and paclitaxel for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC).
Mvasi is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers, including in combination for metastatic carcinoma of the colon or rectum; metastatic breast cancer; for unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer; for non-squamous NSCLC; renal cell cancer; for ovarian, fallopian tube, or primary peritoneal cancer; and carcinoma of the cervix.
Although there are a small number of studies showing some utility in identifying HCC as opposed to metastatic carcinoma to the liver, we have found the high level of sensitivity and specificity of arginase-1 to surpass the use of glypcian-3 in this setting.

Full browser ?